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Summary
 
CCR5 is a chemokine receptor expressed by T cells and macrophages, which also functions as
the principal coreceptor for macrophage (M)-tropic strains of HIV-1. To understand the mo-
lecular basis of the binding of chemokines and HIV-1 to CCR5, we developed a number of
mAbs that inhibit the various interactions of CCR5, and mapped the binding sites of these
mAbs using a panel of CCR5/CCR2b chimeras. One mAb termed 2D7 completely blocked
the binding and chemotaxis of the three natural chemokine ligands of CCR5, RANTES (reg-
ulated on activation normal T cell expressed and secreted), macrophage inflammatory protein
(MIP)-1
 
a
 
, and MIP-1
 
b
 
, to CCR5 transfectants. This mAb was a genuine antagonist of CCR5,
since it failed to stimulate an increase in intracellular calcium concentration in the CCR5 trans-
fectants, but blocked calcium responses elicited by RANTES, MIP-1
 
a
 
, or MIP-1
 
b
 
. This mAb
inhibited most of the RANTES and MIP-1
 
a
 
 chemotactic responses of activated T cells, but
not of monocytes, suggesting differential usage of chemokine receptors by these two cell types.
The 2D7 binding site mapped to the second extracellular loop of CCR5, whereas a group of
mAbs that failed to block chemokine binding all mapped to the NH
 
2
 
-terminal region of
CCR5. Efficient inhibition of an M-tropic HIV-1–derived envelope glycoprotein gp120 bind-
ing to CCR5 could be achieved with mAbs recognizing either the second extracellular loop or
the NH
 
2
 
-terminal region, although the former showed superior inhibition. Additionally, 2D7
efficiently blocked the infectivity of several M-tropic and dual-tropic HIV-1 strains in vitro.
These results suggest a complicated pattern of HIV-1 gp120 binding to different regions of
CCR5, but a relatively simple pattern for chemokine binding. We conclude that the second
extracellular loop of CCR5 is an ideal target site for the development of inhibitors of either
chemokine or HIV-1 binding to CCR5.
 
C
 
hemokines mediate a range of proinflammatory effects
on leukocytes, such as chemotaxis, degranulation, and
integrin activation (1–3). The chemokines have been di-
vided into four families, based on the configuration of cys-
teine residues near the NH
 
2
 
 terminus. The CC family,
which includes macrophage inflammatory protein (MIP)-
1
 
a
 
,
 
1
 
 MIP-1
 
b
 
, RANTES (regulated on activation normal
T cell expressed and activated), monocyte chemotactic
protein (MCP)-1, -2, -3, and -4, are generally chemotactic
for T cells, monocytes, basophils, and eosinophils (1–5) but
not neutrophils. These chemokines attract leukocytes by
binding to the seven transmembrane–spanning G-protein
coupled receptors CCR1 through CCR8 (1, 6–9). The
expression of chemokine receptors on leukocytes directs
leukocyte chemotactic responses to particular sets of chemo-
kines, both in vitro and in vivo (5, 10–14). The chemokine
receptor CCR5 appears to be one of the important recep-
tors for directing the migration of activated and effector T
cells, since these T cells respond robustly to the CCR5
ligands RANTES, MIP-1
 
a
 
, and MIP-1
 
b
 
 in chemotaxis as-
says (15–18), and CCR5 is expressed at high levels on these
 
1
 
Abbreviations used in this paper:
 
 M, macrophage; MCP, monocyte chemo-
tactic protein; MIP, macrophage inflammatory protein; RANTES, regu-
lated on activation normal T cell expressed and secreted.
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cells (19). The precise role of other chemokine receptors
on T cells has been difficult to assess, since specific reagents
or receptor antagonists have not been available.
Chemokine receptors also serve as coreceptors for HIV-1
entry into cells. CCR5 is the principal coreceptor for pri-
mary macrophage (M)-tropic HIV-1 strains (20–24) , while
CXCR4 supports infection of CD4
 
1
 
 cells by T-tropic
HIV-1 strains (25). The envelope glycoprotein gp120 of
HIV-1, upon binding to CD4, interacts specifically with
the coreceptors (26–28). The importance of CCR5 for
HIV-1 transmission is underscored by the findings that in-
dividuals who have a defect in CCR5 expression are gen-
erally resistant to infection with HIV-1 (29–32). In addi-
tion, CD4
 
1
 
 T cells from these individuals are also highly
resistant in vitro to the entry of primary M-tropic HIV-1
(29, 33). This resistance results from a defective CCR5 al-
lele that contains an internal 32-bp deletion (CCR5 
 
D
 
32).
To date, no immunological defects have been noted in ei-
ther CCR5 
 
D
 
32 homozygous or heterozygous individuals.
The resistance of CCR5 
 
D
 
32 homozygous individuals to
infection with HIV-1 has prompted a widespread effort to
develop antagonists of CCR5 that may be used therapeuti-
cally to inhibit HIV-1 transmission or to delay progression
to AIDS (34).
Recently, much attention has been focused on the mo-
lecular interactions of CCR5 with HIV-1, as well as the
interactions of CCR5 with its natural CC chemokine
ligands (35–40). Understanding the nature of these interac-
tions should help in the development of antagonists of
CCR5, to inhibit either HIV-1 or chemokine binding.
One approach to probe the interactions of CCR5, and to
block these interactions, is to use mAbs. A panel of mAbs
to CCR5 has recently been produced (19), and these mAbs
inhibit M-tropic HIV-1 infection of T cells. Here we used
a panel of anti-CCR5 mAbs to inhibit either chemokine
binding and function or HIV-1 gp120 binding and HIV-1
infection. We used CCR5/CCR2b chimeras to map the
domains on CCR5 recognized by these mAbs, and correlated
inhibitory activity with the domain specificity of the mAbs.
 
Materials and Methods
 
CCR5/CCR2 Chimeras.
 
Several CCR5/CCR2 chimeras
(C25-01 to C25-14) were constructed by transferring restriction
fragments flanked by the common BamHI, AfIII, ClaI, EcoRI,
and XbaI sites between CCR5 and CCR2b. The construction
and characterization of these chimeras have been previously de-
scribed (35). The constructs were transferred into a bicistronic vector
(41), under dependence of the elongation factor 1a promoter, and
transfected in Chinese hamster ovary-K1 cells as previously described
(42). G418-resistant cell populations were used in FACS
 
Ò
 
 analyses.
 
Cells and Cell Lines.
 
PBMCs were isolated as described (5).
The CD3
 
1
 
 blasts were generated using anti-CD3 antibody TR77
and maintained in medium supplemented with recombinant human
IL-2 as previously described (19). Other cell lines used included
THP-1 and transfectants of the L1.2 murine pre–B cell lym-
phoma, expressing high levels of CCR5 (19, 26) or CXCR4.
The different transfectants were monitored for expression of the
relevant receptors, using specific mAbs (15, 19).
 
Chemokine and HIV-1 gp120 Binding.
 
125
 
I-labeled human
RANTES, MIP-1
 
a
 
, and MIP-1
 
b
 
 were purchased from DuPont-
NEN (Boston, MA), and unlabeled chemokines were from Pep-
roTech, Inc. (Rocky Hill, NJ). Chemokine binding to target cells
was carried out using a modification of a method previously re-
ported (26, 43). CCR5 L1.2 cells or CD3
 
1
 
 blasts were washed
and resuspended in binding buffer (50 mM Hepes, pH 7.5, 1 mM
CaCl
 
2
 
, 5 mM MgCl
 
2
 
, and 0.5% BSA) at 5 
 
3
 
 10
 
6
 
/ml. For each
binding reaction (in a final volume of 100 
 
m
 
l), 25 
 
m
 
l of cell sus-
pension (1.25 
 
3
 
 10
 
5
 
 cells) was mixed with 0.1 nM radio-labeled
chemokine with or without an appropriate amount of anti-
CCR5 mAb, or an isotype-matched control mAb. Total binding
was in the presence of radiolabeled chemokines only, and non-
specific binding (background) was determined in the presence of
100 nM unlabeled chemokines. The reactions were incubated at
room temperature for 45–60 min, and stopped by transferring the
mixture to GFB filter plates which were then washed 2–3 times
with binding buffer containing 0.5 M NaCl. The plates were
dried and MicroScint scintillation fluid (Packard Instrument
Company Inc., Meriden, CT) was added before counting. Each
sample was assayed in duplicate. The envelope gp120 protein de-
rived from HIV-1 JR-FL (27; gift from Paul Maddon, Progenics
Pharmaceuticals, Inc. Tarrytown, NY) was iodinated using solid
phase lactoperoxidase to a specific activity of 20 
 
m
 
Ci/
 
m
 
g. Binding
to target cells was performed similarly as for radiolabeled chemokine
binding, except that soluble CD4 was included in the assays, as
previously reported (26).
 
mAbs, Immunofluorescent Staining, and FACS
 
Ò
 
 Analysis.
 
mAb 2D7
reactive with CCR5 was generated by immunizing mice with
L1.2 cells expressing high levels of transfected CCR5, as previously
described (19). C57BL6 mice were immunized with 10
 
7
 
 cells, in-
traperitoneally, six times at 2-wk intervals, and 4 d after an intra-
venous injection, the spleen was removed and cells were fused
with the SP2/0 cell line. The mAb generated, 2D7, was deter-
mined to be IgG1. Other mAbs used in this study included 5A11,
an anti-CCR2b mAb (15), PE-conjugated 12G5, an anti-CXCR4
mAb (44; PharMingen, San Diego, CA), and 3A9, an anti-CCR5
mAb (19). The reactivity of mAbs against transfected cells or leu-
kocytes was assessed using indirect immunofluorescence and flow
cytometry techniques as previously described (19).
 
Chemotaxis Assays.
 
Chemotaxis experiments with human
PBMC, or CD3-activated, IL-2–stimulated T cells, employed the
cell line ECV304 to coat Biocoat
 
Ò
 
 Transwell tissue culture inserts
(Collaborative Biomedical Products, Bedford, MA), exactly as
previously described (5). Chemotaxis with L1.2 receptor transfec-
tant cell lines was carried out similarly except that endothelial
cells were not used to coat the Biocoat
 
Ò
 
 Transwell tissue culture
inserts and the incubation was for 4–6 h (45). Cells migrating to
the bottom chamber of the Transwell were enumerated using the
FACScan
 
Ò
 
, by counting cells for 30 s. Tight forward angle and
side scatter gates were set to exclude debris or irrelevant cells.
 
Measurement of [Ca
 
2
 
1
 
]
 
i
 
.
 
Cells were labeled with the fluoro-
chrome Fura-2 AM (Molecular Probes, Eugene, OR), as previously
described (14). In brief, Fura-2 AM was added to the cell suspension
to produce a final concentration of 0.2 mol/10
 
6
 
 cells. After incuba-
tion at 37
 
8
 
C for 30 min, excess dye was removed by centrifugation
and cells were resuspended at a concentration of 10
 
6
 
/ml in 125 mM
NaCl, 5 mM KCl, 1 mM MgCl
 
2
 
, 1 mM CaCl
 
2
 
, 0.5 mM glucose,
0.025% BSA, and 20 mM Hepes, pH 7.4. [Ca
 
2
 
1
 
]
 
i
 
 was measured
using excitation at 340 and 380 nm on a Hitachi F-2000 fluorescence
spectrometer. Calibration was performed using 1% NP-40 for to-
tal fluorophore release and 25 
 
m
 
M EGTA to chelate free Ca
 
2
 
1
 
.
 
Inhibition of HIV-1 Infection by Anti-CCR5 mAb 2D7.
 
Inhibi- 
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tion of HIV-1 infection in U87-CD4-CCR5 cells was deter-
mined using a virus entry assay based on single-cycle infection.
Cells were infected with the env-deficient virus NL4/3 luc (46)
complemented in trans with envelope glycoproteins from several
clones. Infection of the cells was measured by quantification of
luciferase activity. In brief, U87-CD4-CCR5 cells (gift from D.
Littman, New York University Medical Center, New York; see
reference 47) were split to a concentration of 5 
 
3
 
 10
 
4
 
 cells/ml,
and 100 
 
m
 
l was added to each well of a 96-well tissue culture
plate. The following day, the cells were washed with PBS and
preincubated with dilutions of mAb 2D7, an isotype-control
(IgG1) mAb, or medium only in a total volume of 40 
 
m
 
l for 1 h
at 4
 
8
 
C. 50 
 
m
 
l of HIV-1 (
 
env
 
 genes of ADA, JR-FL, DH123, or
HxB2, stocks of 100 ng/ml, as measured by p24) was added, and
the cells were incubated with the mAb and the virus for 2 h at
37
 
8
 
C. The cells were then washed, fresh medium was added im-
mediately, and added again after 48 h. 72 h after infection, the
cells were washed with PBS and lysed in 50 
 
m
 
l of 1
 
3
 
 reporter ly-
sis buffer (Promega Corp., Madison, WI). To measure luciferase
activity, 100 
 
m
 
l of luciferase substrate (Promega Corp.) was added
to 30 
 
m
 
l of the cell lysate.
 
Results
 
Generation of Anti-CCR5 mAbs that Recognize Different
Domains of CCR5.
 
We sought to generate mAbs to
CCR5 to inhibit the various functions of this molecule,
and to understand how different CCR5 domains bind
chemokines and HIV-1. We have previously described
anti-CCR5 mAbs that inhibit HIV-1 binding, but not
chemokine binding (19). New mAbs to CCR5 were gen-
erated by immunizing C57BL6 mice with the murine pre–B
cell lymphoma line, L1.2, which expresses high levels of
transfected human CCR5. An mAb, termed 2D7, reacted
with CCR5-transfected L1.2 cells, as well as Chinese ham-
ster ovary cells expressing certain portions of CCR5 (see
Fig. 2), but not with L1.2 cells expressing CXCR4 (Fig. 1)
or various other receptors, including CCR2b (not shown).
Moreover, 2D7 showed an identical pattern of reactivity
against human leukocytes, as previously noted for our other
anti-CCR5 mAbs (19, 48). In particular, it stained mostly
the CXCR4
 
2
 
 subset of human PBL (Fig. 1 
 
B
 
), as well as a
subset of tissue macrophages (not shown).
To determine how chemokines or HIV-1 interacts with
CCR5, a series of chimeric receptors was generated by re-
placing extracellular domains of CCR5 with the corre-
sponding domain of CCR2b, or vice versa, using common
restriction sites in regions conserved between the two mol-
ecules (35). The chimeras of CCR5 and CCR2b were
ideal for this purpose, since these two receptors are closely
related but have completely different ligand binding prop-
erties. The interaction of these chimeras with different
strains of HIV-1 has already been reported (35). Fig. 2
shows the panel of chimeras that was used in the present
experiments, and the reactivity of these chimeras to several
mAbs. The 2D7 mAb reacted with all chimeras that con-
tained the second extracellular loop of CCR5. In particular,
C25-14, a chimera comprising CCR2b with the second
extracellular loop of CCR5, was stained intensely by mAb
2D7. In contrast, the anti-CCR5 mAb 3A9 (as well as
seven other previously reported anti-CCR5 mAbs) reacted
only with chimeras that contained the NH
 
2
 
-terminal re-
gion of CCR5 (Fig. 2). In addition, mutants of CCR5
lacking the NH
 
2
 
-terminal eight amino acids were not reac-
tive with mAb 3A9, suggesting that the epitope for this
mAb was dependent on the very NH
 
2
 
 terminus of the mol-
ecule. An mAb to CCR2b, 5A11, stained all chimeras con-
taining the NH
 
2
 
 terminus of CCR2b, consistent with the
fact that this mAb was raised against a synthetic peptide
comprising the 32 NH
 
2
 
-terminal amino acids of CCR2b (15).
 
The Second Extracellular Loop mAb, but Not the NH
 
2
 
 Ter-
minus–specific mAbs, Blocks MIP-1
 
a
 
, MIP-1
 
b
 
, and RANTES
Binding to CCR5 Transfectants, as well as to Activated T
Cells.
 
A preliminary analysis of a panel of anti-CCR5
mAbs revealed that none of the eight previously identified
anti-CCR5 mAbs was able to block the binding of the
CCR5 ligands RANTES, MIP-1
 
a
 
, or MIP-1
 
b
 
 to CCR5
L1.2 transfectants. The ability of mAb 2D7 to inhibit the
binding of these chemokines was assessed. Fig. 3 
 
A
 
 shows
that 10 
 
m
 
g/ml of mAb 2D7 was able to inhibit completely
the binding of 
 
125
 
I-labeled human RANTES, MIP-1
 
a
 
, and
MIP-1
 
b
 
 to CCR5 L1.2 transfectants. An analysis with de-
Figure 1. mAb 2D7 recognizes CCR5 specifically. (A) Reactivity of
mAb 2D7 with CCR5 L1.2 cells, but not with CXCR4 L1.2 cells. (B)
Two color staining of human PBL with 2D7 (green fluorescence, x-axis)
and 12G5 (anti-CXCR4, red fluorescence, y-axis). Quadrants were set on
the basis of control and single color stainings.1376 Inhibition of HIV-1 and Chemokine Binding to CCR5
creasing amounts of mAb 2D7 established an inhibitory
constant (IC)50 of 23 ng/ml for MIP-1a binding, 41 ng/ml
for MIP-1b binding, and 58 ng/ml for RANTES binding
(not shown). mAb 3A9, directed to the NH2 terminus of
CCR5, caused minimal inhibition of binding of the three
chemokines at 10 mg/ml (Fig. 3 A), and only slight inhibi-
tion at concentrations up to 100 mg/ml (not shown).
THP-1 cells, which do not express CCR5 (19), were also
examined as a specific control. These cells bound MIP-1a
(Fig. 3 B) and RANTES (not shown), and mAb 2D7 had
no effect on the level of binding.
125I-labeled RANTES, –MIP-1a, and –MIP-1b binding
to activated T cells is shown in Fig. 3 C. These three
chemokines bound to IL-2–maintained T cells, and this
binding could be competed with 100 nM unlabeled
chemokine. T cells from day 21 after activation showed the
highest level of binding and chemotactic responses to the
three chemokines (see below). mAb 2D7 was assessed for
its ability to compete for binding of these CC chemokines.
At 10 mg/ml, 2D7 completely blocked the MIP-1b bind-
ing to these activated T cells. Under the same conditions,
125I-RANTES and 125I–MIP-1a binding were inhibited by
95 and 85%, respectively. This result indicated that CCR5
was responsible for most of the RANTES, MIP-1a, or
MIP-1b binding to these T cells. Nevertheless, some varia-
tions were noted in the 2D7 inhibition level when using T
cells from different time points (10–26 d). At earlier time
points, fewer RANTES and MIP-1a binding sites were
blocked by mAb 2D7.
mAb 2D7 Inhibits CCR5 Functional Responses to MIP-1a,
MIP-1b, and RANTES. The agonist/antagonist activity
of mAb 2D7 was tested on CCR5 L1.2 transfectants, by
measuring whether there was a change in intracellular cal-
cium concentration [Ca21]i of Fura-2–loaded cells in re-
sponse to various concentrations of mAb 2D7. mAb 2D7
itself failed to stimulate a change in [Ca21]i in CCR5 L1.2
cells, but was able to inhibit subsequent stimulation by
MIP-1a (Fig. 4) as well as by RANTES and MIP-1b (not
shown). mAb 2D7 did not inhibit a change in [Ca21]i after
stimulation with stromal cell–derived factor–1, which op-
erates through an endogenous mouse CXCR4 receptor.
Incubation of CCR5 L1.2 cells with a control mAb
(MOPC-21) had no inhibitory effect. In addition, neither
mAb 3A9 nor any of the other CCR5 NH2-terminal–spe-
cific mAbs had any inhibitory effect on the RANTES-,
MIP-1a– and MIP-1b–mediated Ca21 flux responses.
mAb 2D7 inhibited the chemotaxis of CCR5 L1.2 cells
to RANTES, MIP-1a, and MIP-1b, in a dose-dependent
manner (Fig. 5 A). Incubation of cells with 20 mg/ml of
mAb in the top chamber was sufficient to achieve complete
inhibition of migration to all three chemokines. The ability
to achieve complete inhibition with 2D7 allowed us to ex-
amine the significance of CCR5 for lymphocyte, mono-
cyte, and activated T cell responses to RANTES, MIP-1a,
and MIP-1b. As shown in Fig. 5 B, chemotactic responses
by blood lymphocytes to MIP-1b were almost completely
inhibited by 2D7, consistent with the notion that MIP-1b
binds only CCR5 and not other receptors. RANTES re-
sponses were also inhibited in most individuals, but MIP-1a
responses were not. mAb 2D7 showed no dose-dependent
inhibition of monocytes to RANTES or MIP-1a (Fig. 5
C). This result is consistent with previous studies showing
Figure 2. Reactivity of CCR5-specific mAbs with CCR5/CCR2b re-
ceptor chimeras. The structures of CCR5/CCR2b chimeras used in this
study are shown schematically on the left-hand side. Regions derived
from CCR5 are shown in light gray, and regions derived from CCR2b
are shown in black. Stable Chinese hamster ovary cell transfectants ex-
pressing various CCR5/CCR2b receptor chimeras were stained with
anti-CCR5 mAb 3A9, 5C7, 2D7, anti-CCR2b mAb 5A11, or anti-
CXCR1 mAb 7D9. The level of staining of the transfectants by the vari-
ous mAbs was graded 1 to 111, or negative (neg).1377 Wu et al.
minimal expression of CCR5 on most monocytes (19). T
cells stimulated in vitro with anti-CD3 and maintained
with IL-2 for 3 wk showed a very robust chemotactic re-
sponse to RANTES, MIP-1a, and MIP-1b (Fig. 5 D). T
cells maintained in culture for shorter periods of time also
responded, although not quite as robustly (not shown). Im-
portantly, mAb 2D7 was able to inhibit most of the func-
tional chemotactic responses of these T cells to RANTES
and MIP-1b, and z60–80% of the chemotactic response to
MIP-1a. However we did note individual-to-individual
variation. These results were supported by studies with T
cell lines from D32 homozygous individuals, in that the
MIP-1a and RANTES chemotactic responses were mark-
edly impaired in these cells (data not shown).
Inhibition of gp120 Binding to CCR5 and HIV-1 Infection Is
Manifest by mAbs Recognizing Either the NH2 Terminus or the
Second Extracellular Loop. The exterior envelope glyco-
protein gp120 of M-tropic primary HIV-1, upon binding
to CD4, can interact with CCR5 specifically and with high
affinity (26, 27). To assess the ability of the various anti-
CCR5 mAbs to inhibit this interaction, we performed
binding assays using 125I-labeled gp120 derived from HIV-1
JR-FL (an M-tropic strain; reference 27) in the presence or
absence of 3A9 or 2D7 (Fig. 6 A). mAb 2D7 inhibited effi-
ciently the binding of 125I-gp120 to CCR5 L1.2 cells, in
the presence of soluble CD4, with an inhibitory constant
(IC)50 of z20 ng/ml. At a concentration of 100 ng/ml, 2D7
inhibited the 125I-gp120 binding to the same level as that
Figure 3. mAb 2D7 inhibits
the binding of 125I–MIP-1a,
–MIP-1b, and -RANTES to
CCR5. CCR5 L1.2 cells (A),
THP1 cells (B), or day 15–acti-
vated IL-2–stimulated CD3 blast
T cells (C) were incubated with
0.1 nM 125I-labeled–MIP-1a,
–MIP-1b, or -RANTES, in the
absence (total binding) or pres-
ence of either 10 mg/ml of mAb
2D7 (an IgG1 isotype), mAb
3A9, control IgG1 mAb, or 100
nM unlabeled chemokine. After
45–60 min at room temperature,
cells were washed and counted as
described in Materials and Meth-
ods. Data are shown as the per-
centage of total binding, i.e., in
the absence of mAb or unlabeled
chemokines.
Figure 4. mAb 2D7 inhibits
[Ca21]i flux in CCR5 L1.2 cells
in response to MIP-1a. CCR5
L1.2 cells were labeled with
Fura-2 as described in Materials
and Methods, and stimulated se-
quentially with mAb, followed
40 s later with MIP-1a, and 100 s
with SDF-1. [Ca21]i fluores-
cence changes were recorded us-
ing a spectrofluorometer. The
tracings were representative of
three separate experiments. In
the top panel, an irrelevant mAb
(MOPC-21) was used, and in
the bottom panel, mAb 2D7.
Antibodies were used at a final
concentration of 20 mg/ml.
MIP-1a was used at 100 nM and
SDF-1 was used at 200 nM.
Figure 5. Inhibition of chemotactic responses of various cell types to
MIP-1a, MIP-1b, and RANTES, using mAb 2D7. A, CCR5 L1.2 cells;
B, blood lymphocytes; C, blood monocytes; and D, day 21 activated, IL-
2–stimulated T cells. For these experiments, 106 cells were placed in the
top chamber of the Transwell and an optimal concentration of chemo-
kine (usually 12.5 nM) was placed in the bottom chamber. Various con-
centrations of 2D7 mAb were placed in the top well. After various peri-
ods of time (1–4 h) the cells migrating to the bottom chamber were
counted using flow cytometry. The results are representative of at least
four separate experiments. Untransfected L1.2 cells showed no migration
to MIP-1a, MIP-1b, or RANTES (data not shown). Chemotactic index
was calculated by dividing the number of migrated cells in response to a
specific chemokine by that in the absence of chemokine (background).
The background values for these cells are: 28 (CCR5 L1.2), 136 (lym-
phocytes), 507 (monocytes), and 615 (CD3 blasts).1378 Inhibition of HIV-1 and Chemokine Binding to CCR5
obtained with excess unlabeled gp120. In contrast, mAb
3A9, at the low concentration range, had a moderate in-
hibitory effect on the 125I-gp120 binding, but inhibited
completely at a higher concentration (>100 mg/ml). An
isotype-control mAb had no significant inhibitory effect at
a concentration up to 100 mg/ml.
To study the inhibitory effect of 2D7 on HIV-1 entry,
we employed a virus entry assay based on single-cycle in-
fection using several viral strains. As shown in Fig. 6 B, the
U87MG-CD41 cells expressing transfected CCR5 (47) can
be efficiently infected by M-tropic (ADA and JR-FL env)
and dual-tropic (DH123 env) chimeric viruses, which can
use CCR5 as coreceptor, but not by the T cell–tropic chi-
mera (HxB2), which uses only CXCR4. mAb 2D7 effi-
ciently inhibited the entry of the dual-tropic DH123 chi-
mera (.90% inhibition at 1 mg/ml), whereas a higher
concentration of 2D7 (z10 mg/ml for z90% inhibition)
was required for inhibiting the M-tropic (ADA and JR-FL)
strains.  Under the same conditions, the isotype-control
mAb had no significant effect. mAb 3A9 showed little ef-
fect on the HIV-1 entry of U87-CD4-CCR5 cells, but it
could effectively neutralize the infection of PBMC by
M-tropic HIV-1 strains as previously shown (19).
Discussion
In this study, we sought to develop and use blocking
anti-CCR5 mAbs to determine the important regions on
CCR5 for chemokine binding and HIV-1 gp120 interac-
tions. Additionally, we used the blocking mAb to deter-
mine the importance of CCR5 for T cell and monocyte
responses to RANTES, MIP-1a, and MIP-1b.
Identifying regions of CCR5 that facilitate HIV-1 gp120
binding, or chemokine binding, is important for under-
standing the molecular basis of CCR5 interactions, and for
developing inhibitors of these interactions. Results from
several studies imply that gp120 binds to CCR5 via multi-
ple domains (35, 36, 38, 40). However, different conclu-
sions have been reached as to the importance of the various
extracellular domains of CCR5 for HIV-1 interactions.
Previous studies with the panel of CCR5/CCR2b recep-
tor chimeras used here showed that the NH2 terminus of
CCR5, as well as the first extracellular loop (but not the
second extracellular loop), were important for M-tropic
HIV-1 binding (35). In contrast, studies by Bieniasz et al.
(38), using 89.6 and ADA, found that the second extracel-
lular loop was important for binding. Using human/mouse
CCR5 chimeras, they showed that ADA could utilize a
chimeric receptor containing any single human CCR5 ex-
tracellular domain, while BaL required any two human ex-
tracellular domains, and 89.6 required three domains (38).
Regardless of the way different strains of HIV-1 bind to
CCR5, another issue is how to develop agonists or antago-
nists that can inhibit HIV-1 binding to various regions of
CCR5. To date, the most effective inhibitors of HIV-1
binding to CCR5 have been CC chemokines, or modified
forms of them (21, 23, 24, 49–51). Here we show that an
anti-CCR5 mAb 2D7, which recognizes the second extra-
cellular loop, was able to completely inhibit the binding of
JR-FL gp120 to CCR5, and to efficiently block the entry
of M-tropic (ADA and JR-FL) and dual-tropic (DH123)
HIV-1 strains. Anti-CCR5 mAbs that mapped to the NH2
terminus were also able to inhibit M-tropic HIV-1 gp120
binding or viral entry into T cells, albeit somewhat less po-
tently. This is consistent with studies using CCR5/CCR2b
chimeras which show that M-tropic HIV-1 binding relies
on the NH2 terminus and the first extracellular loop (35).
It has been shown recently that the binding of HIV-1
and chemokines to the coreceptor are nonoverlapping
functions of CCR5 (36, 37, 39). All evidence implicates
the second extracellular loop of CCR5 as the principal bind-
ing element for RANTES, MIP-1a, or MIP-1b (51a;
Charo, I., personal communication). Consistent with this,
mAb 2D7 to the second extracellular loop was able to in-
Figure 6. Inhibition of 125I-gp120 binding and HIV-1 infection by
anti-CCR5 mAbs. (A) Inhibition of 125I-labeled M-tropic HIV-1 JR-FL
gp120 binding to CCR5 L1.2 transfectants by mAb 2D7 and 3A9. CCR5
L1.2 cells were incubated with 0.2 nM 125I-labeled gp120 and 20 nM
sCD4 in the absence or presence of increasing concentrations of mAb
2D7 or 3A9. After 60 min at room temperature, cells were washed and
counted as described in Materials and Methods. An IgG1 control mAb
was used as a control. 100% of inhibition was defined as that caused by
100 nM of unlabeled gp120. (B) Inhibition of HIV-1 infection in U87-
CD4-CCR5 cells by mAb 2D7. The infectability of U87-CD4-CCR5
cells by M-tropic (ADA and JR-FL), dual-tropic (DH123), and T-tropic
(HxB2) HIV-1 strains, in the absence or presence of increasing concen-
trations of 2D7 or 50 mg/ml of an IgG1 control mAb, was determined us-
ing a virus entry assay based on single-cycle infection as described in Ma-
terials and Methods. Infection of the cells was measured by quantification
of luciferase activity.1379 Wu et al.
hibit totally the binding of RANTES, MIP-1a, and MIP-
1b, whereas mAbs recognizing the NH2 terminus of
CCR5 were ineffective. The different effect between the
two panels of mAbs is unlikely due to their different bind-
ing affinities to the receptor, since all eight mAbs directed
to the NH2 terminus showed a similar lack of inhibitory
activity. Furthermore, the inhibitory effect of 2D7 on
chemokine and HIV-1 binding did not result from recep-
tor downmodulation, since the same level of CCR5 cell
surface staining was detected on CCR5 L1.2 cells that were
preincubated with 2D7 for 1 h at room temperature and on
those that were not preincubated (Kassam, N., and L. Wu,
unpublished results). Therefore, whereas the specificity of
CC chemokine binding to CCR5 is determined by a single
domain, the gp120 binding site is more complex and prob-
ably involves at least two domains, although changes in the
NH2 terminus can be sufficient and can significantly affect
gp120 binding and HIV-1 entry. It is conceivable that the
ability of an mAb to inhibit HIV-1 binding may have more
to do with steric hindrance rather than with direct inter-
ruption of the binding sites.
We predict that mAb 2D7 will block the binding to
CCR5 of most HIV-1 strains that can use this coreceptor,
as exemplified here with ADA, JR-FL, and DH123, and by
other studies which indicate that 2D7 is able to block the
replication of a wide range of primary isolates in PBMC
(Wilkinson, P., and R. Koup, personal communication).
The potential to disrupt HIV-1 gp120 binding with agents
that interfere with either the NH2 terminus or the second
extracellular loop suggests that small molecule antagonists
that can bind to different parts of CCR5 might also be ef-
fective at blocking CCR5-gp120 interactions. Since mAb
2D7 can efficiently block all known functions of CCR5,
the second extracellular loop might be a particularly good
target for the development of small molecule antagonists.
Much confusion has surrounded the chemotactic responses
of T cells to chemokines (52), as well as the qualitative and
quantitative aspects of chemokine receptor expression. mAbs
have proven to be a powerful tool for dissecting chemo-
kine receptor expression and function on leukocytes (14).
Our results and those of others show that a subset of mem-
ory/effector T cells responds to RANTES, MIP-1a, and
MIP-1b in chemotaxis assays (15, 53). Candidate receptors
that could be mediating these responses include CCR1,
CCR3, CCR4, and CCR5. The use of anti-CCR5 mAbs
demonstrated that CCR5 is expressed intensely on a subset
of memory T cells, as well as on activated, IL-2–stimulated
T cell lines (19). In addition, CCR5 is the only receptor
yet known to bind MIP-1b. We do not now have reagents
to examine CCR1 or CCR4 expression on the cell surface,
so our approach in this study was to inhibit CCR5 func-
tion and assess the remaining ligand binding and functional
responses to RANTES, MIP-1a, and MIP-1b by various
cell types. The mAb 2D7 inhibited most of the MIP-1b
(.95%) and RANTES (.90%), and partially inhibited the
MIP-1a (60–80%) chemotactic responses by activated T
cells. These results suggest that although CCR5 is probably
the only MIP-1b receptor and the predominant RANTES
receptor on T cells, other receptors as well as CCR5 play a
role for MIP-1a responses. CCR1 responds to MIP-1a
and its message is clearly upregulated in IL-2–stimulated T
cell lines, and is thus a likely candidate. However, the as-
sessment of actual receptor expression will have to await
the development of specific mAbs.
In contrast to T cells, monocytes responded to RANTES
and MIP-1a through a receptor other than CCR5. This
result is consistent with the low level of CCR5 expression
that is found on most circulating monocytes (19). How-
ever, CCR5 is upregulated on monocytes after their activa-
tion in vitro (our unpublished results), and is also expressed
by a population of tissue macrophages (19). The receptor
on circulating monocytes which mediates the RANTES
and MIP-1a function could be CCR1. Thus, there appears
to be a relatively good dichotomy in receptor expression;
CCR5 on T cells, and CCR1 on monocytes, although these
receptors are not restricted to these two leukocyte lineages.
The role of CCR1 on monocytes and T cells will be
understood better after the development of a reliable antag-
onistic mAb.
In conclusion, we identified the second extracellular
loop of CCR5 as an important target site for developing
inhibitors of CC chemokine binding as well as HIV-1
gp120 binding to CCR5. Hopefully, future studies will de-
termine the suitability of CCR5 antagonists as therapeutics
for inflammation or HIV-1 infection.
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